Tirzepatide. Two pathways. One injection.
A dual GLP-1 / GIP receptor agonist that engages two incretin pathways in one molecule. Weekly subcutaneous injection. Compounded in the USA under 503A rules for patients who clinically qualify.
Compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA. Rx required.
Dose-banded pricing
RxPick the plan your clinician prescribes.
Compounded tirzepatide is dosed in titration steps. Your clinician selects the band based on your intake, history, and response. Lower doses are where most patients start.
Starter
2.5 – 5 mg
$329/month
Standard
7.5 – 10 mg
$429/month
Maintenance
12.5 – 15 mg
$549/month
$49 consult fee, refunded as your first-month credit if your clinician approves you, or refunded in full if no prescription is issued.
Auto-renews monthly after clinician approval. Pause or cancel any time before your next ship date. 48-hour refund window on first charge.
Compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA. Rx required.
What it is
The newest generation of incretin-based therapy.
Tirzepatide is a synthetic peptide that activates two incretin receptors, GLP-1 and GIP, in a single molecule. Both hormones are released by the gut in response to food; together they regulate insulin, glucagon, appetite, and gastric motility.
Branded tirzepatide products are FDA-approved finished drugs. Compounded tirzepatide is a different thing: prepared by a US-licensed 503A pharmacy under a clinician’s prescription, for patients with documented clinical need under the “not essentially a copy” framework. It is not FDA-approved.
At PepScribe, compounded tirzepatide is prescribed as a specialty line, when a compounded formulation is clinically appropriate, not as a generic substitute for the branded product.
How it works
Mechanism of action.
Dual incretin action
Activates both GLP-1 and GIP receptors simultaneously. These incretins work through complementary pathways, together they produce stronger effects on appetite and glucose regulation than either alone.
Appetite + glucose regulation
Combined GLP-1/GIP engagement may produce greater effects on appetite regulation and glycemic control than GLP-1 agonism alone, based on published clinical data.
Once-weekly pharmacokinetics
Long half-life supporting once-weekly subcutaneous dosing. Steady-state levels reached over the first several weeks on a titrated protocol.
Who it’s for
Clinician-reviewed, not everyone qualifies.
A licensed clinician reviews your intake and recommends tirzepatide only when clinically appropriate under 503A compounding rules. Free assessment. Your consult fee credits toward your first month if approved, or refunded in full if no prescription is issued.
- Considered for adults with clinical eligibility for dual-incretin therapy
- Your clinician reviews your history for thyroid conditions (MTC/MEN2), pancreatitis, and pregnancy
- Not prescribed during pregnancy, active thyroid malignancy, or certain GI conditions
- Labs and vitals may be ordered; results inform dose titration
What comes with the plan
Everything included.
- Clinician-prescribed, US-licensed
- Compounded in the USA by a licensed 503A pharmacy
- Flat monthly pricing, medication included
- Supplies and injection instructions
- Async clinician messaging
- HSA and FSA eligible
Compounded tirzepatide is prepared by licensed 503A pharmacies in the USA and is not FDA-approved. The branded injectable tirzepatide products are separate FDA-approved drugs produced by their manufacturers. All prescriptions require approval by a licensed healthcare provider. Individual results may vary.
See if Tirzepatide is a fit.
Three-minute assessment. Clinician review within 48 hours. Your consult fee credits toward your first month if tirzepatide is prescribed.